



Research Letter

Trends in High-Acuity Cardiovascular Events During the COVID-19 Pandemic

J. Franklin Wharam, MD, MPH; Robert F. LeCates, MA; Ann Thomas, PhD, MS; Fang Zhang, PhD; Stephanie Argetsinger, MPH; Laura F. Garabedian, PhD, MPH; Alison A. Galbraith, PhD, MPH

Introduction

The COVID-19 pandemic and subsequent public health measures reduced health care access, potentially delaying time-sensitive cardiovascular disease (CVD) care. Additionally, SARS-CoV-2 infection is associated with higher rates of heart failure, myocardial infarction, and stroke.¹ Population-level analyses reported early reductions in major adverse cardiovascular events (CVEs).²⁻⁵ This pattern raised concerns that subsequent rates might increase beyond expected levels, but longer-term patterns are uncertain. New England was among the earliest- and hardest-hit regions during the pandemic. Analyses of New England populations could provide insights about longer-term pandemic implications for CVD outcomes. We hypothesized that early decreases in adverse CVEs were followed by rates that were higher than those estimated by prepandemic CVE trends.

+ [Invited Commentary](#)

+ [Supplemental content](#)

Author affiliations and article information are listed at the end of this article.

Methods

We studied administrative and claims data from March 2017 to December 2021 from Harvard Pilgrim Health Care, a New England insurer with approximately 1 million members. We included commercial insurance and Medicare Advantage members 35 years or older from Massachusetts, New Hampshire, Maine, and Connecticut with at least 6 enrollment months (eTables 1-5 in [Supplement 1](#)). Harvard Pilgrim Health Care Institutional Review Board approved this cohort study and waived informed consent because deidentified data were used. We followed the [STROBE](#) reporting guideline.

Using claims-based algorithms and a standard approach with high specificity, we measured myocardial infarction and stroke hospitalizations (eMethods and eTable 6 in [Supplement 1](#)). We captured congestive heart failure (CHF), angina, and transient ischemic attack (TIA) episodes in individuals presenting to the emergency department, observation unit, or hospital. We added up the preceding measures to create a composite high-acuity CVE outcome. With an interrupted time series design, we examined monthly event rates before and after March 2020. We ran segmented linear regression models adjusted for age and sex to compare modeled postpandemic trends with expected postpandemic trends. Statistical analysis was performed with Stata 16 (StataCorp LLC).


Results

Member characteristics were similar across the study period, but members had higher socioeconomic status (SES) than state populations. Composite high-acuity CVEs initially decreased in April 2020 by 26.6% (95% CI, -31.4 to -21.8) ([Figure, Table](#)). Rates remained below expected levels in March 2021 (-9.6%; 95% CI, -14.5 to -4.8) and December 2021 (-19.8%; 95% CI, -26.2 to -13.5).

Stroke hospitalizations initially decreased by 27.0% (95% CI, -39.5 to -14.5), remained lower than expected in February 2021 (-11.8%; 95% CI, -23.1 to -0.5), and were below expected levels in December 2021 (-27.3%; 95% CI, -42.4 to -12.2). Myocardial infarction hospitalizations initially decreased by 27.8% (95% CI, -35.8 to -19.8) but were not statistically different from expected by January 2021. Congestive heart failure episodes initially decreased by 26.1% (95% CI, -33.3 to -18.9), were below expected levels in March 2021 (-15.8%; 95% CI, -22.6 to -9.0), and were lower than expected by December 2021

Open Access. This is an open access article distributed under the terms of the CC-BY License.

Figure. Rates per Month of Cardiovascular Events in a Commercially Insured Population 35 Years or Older



The eMethods in Supplement 1 detail the segmented regression models used to generate absolute difference estimates with 95% CIs (represented by gray line with error bars) and observed monthly rates and trends.

^a Comprising stroke, myocardial infarction, congestive heart failure, transient ischemic attack, and angina episodes.

^b Presenting to the hospital.

^c Presenting to the emergency department, observation unit, or hospital.

Table. Absolute and Relative Differences vs Expected Rates in High-Acuity Presentations for Adverse Cardiovascular Events During the COVID-19 Pandemic

Event	Difference vs expected rates (95% CI)				
	April 2020		Smallest relative difference [month of smallest difference during follow-up period]	December 2021	
	Absolute, episodes per 1000 members	Relative, %		Absolute, episodes per 1000 members	Relative, %
Composite high-acuity cardiovascular events ^a	-0.75 (-0.90 to -0.61)	-26.6 (-31.4 to -21.8)	-9.6 (-14.5 to -4.8) [March 2021]	-0.59 (-0.80 to -0.37)	-19.8 (-26.2 to -13.5)
Stroke ^b	-0.07 (-0.10 to -0.03)	-27.0 (-39.5 to -14.5)	-11.8 (-23.1 to -0.5) [February 2021]	-0.07 (-0.12 to -0.03)	-27.3 (-42.4 to -12.2)
Myocardial infarction ^b	-0.16 (-0.22 to -0.11)	-27.8 (-35.8 to -19.8)	-5.1 (-14.8 to 4.5) [June 2021]	-0.06 (-0.14 to 0.02)	-10.0 (-22.4 to 2.5)
Congestive heart failure ^c	-0.26 (-0.34 to -0.18)	-26.1 (-33.3 to -18.9)	-15.8 (-22.6 to -9.0) [March 2021]	-0.24 (-0.36 to -0.12)	-22.1 (-31.5 to -12.7)
Transient ischemic attack ^c	-0.06 (-0.09 to -0.03)	-26.7 (-40.6 to -12.9)	6.2 (-7.2 to 19.6) [March 2021]	-0.03 (-0.07 to 0.02)	-10.6 (-28.0 to 6.8)
Angina ^c	-0.20 (-0.26 to -0.14)	-26.2 (-33.0 to -19.4)	-8.0 (-15.0 to -1.1) [February 2021]	-0.19 (-0.27 to -0.11)	-24.7 (-33.7 to 15.7)

^a Comprising stroke, myocardial infarction, congestive heart failure, transient ischemic attack, and angina episodes. ^c Presenting to the emergency department, observation unit, or hospital.

^b Presenting to the hospital.

(-22.1%; 95% CI, -31.5 to -12.7). Angina episodes followed similar sustained reduction trends, whereas TIA episodes were not statistically different from expected by August 2020.

Discussion

The COVID-19 pandemic was not associated with longer-term increases in adverse CVEs among commercially insured New England residents presenting for care. Instead, we detected sustained reductions in TIA, CHF, and angina episodes. Factors explaining these trends could include lack of patient presentation during the 21-month follow-up, cardiovascular deaths outside the medical system, COVID-19-related deaths of people at risk for high-acuity CVEs, decrease in overdiagnosis due to lower emergency department and hospital volumes, heart failure management at home, and reductions in adverse events. Further studies are needed to identify and quantify such factors.

Study findings might not generalize to other US regions, people without commercial insurance, or populations with lower SES. For example, Massachusetts was unusual for experiencing no increase in cardiovascular deaths during the first 2 pandemic months.⁶ Additional research may examine regions with lower concentrations of clinicians, lower SES, and higher CVD burden. This study, combined with future studies, could help policymakers and insurers anticipate changes in major health outcomes during periods of limited health care access.

ARTICLE INFORMATION

Accepted for Publication: October 23, 2023.

Published: January 5, 2024. doi:10.1001/jamahealthforum.2023.4572

Corresponding Author: J. Franklin Wharam, MD, MPH, Duke University, 710 W Main St, Durham, NC 27701 (jwharam@duke.edu).

Author Affiliations: Department of Medicine, Duke University, Durham, North Carolina (Wharam); Duke-Margolis Center for Health Policy, Durham, North Carolina (Wharam); Department of Population Medicine, Harvard Pilgrim Healthcare Institute, Harvard Medical School, Boston, Massachusetts (Wharam, LeCates, Thomas, Zhang, Argetsinger, Garabedian, Galbraith); Department of Pediatrics, Boston Medical Center and Boston University Chobanian and Avedisian School of Medicine, Boston, Massachusetts (Galbraith).

Open Access: This is an open access article distributed under the terms of the [CC-BY License](https://creativecommons.org/licenses/by/4.0/). © 2024 Wharam JF et al. *JAMA Health Forum*.

Author Contributions: Dr Wharam had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Wharam, Argetsinger.

Acquisition, analysis, or interpretation of data: Wharam, LeCates, Thomas, Zhang, Garabedian, Galbraith.

Drafting of the manuscript: Wharam, Thomas, Argetsinger.

Critical review of the manuscript for important intellectual content: Wharam, LeCates, Thomas, Zhang, Garabedian, Galbraith.

Statistical analysis: Wharam, LeCates, Thomas, Zhang.

Obtained funding: Wharam.

Administrative, technical, or material support: Wharam, LeCates, Argetsinger, Galbraith.

Supervision: Wharam.

Conflict of Interest Disclosures: Dr Wharam, Mr LeCates, Dr Thomas, and Dr Garabedian, and Dr Galbraith reported receiving grants from Harvard Pilgrim Health Care during the conduct of the study. Drs Wharam and Galbraith reported being former employees of Harvard Pilgrim Health Care/Point32Health outside the submitted work. No other disclosures were reported.

Funding/Support: This work was funded by Harvard Pilgrim Health Care.

Role of the Funder/Sponsor: The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Data Sharing Statement: See [Supplement 2](#).

Additional Contributions: Two anonymous unpaid reviewers provided insightful suggestions.

REFERENCES

1. Block JP, Boehmer TK, Forrest CB, et al. Cardiac complications after SARS-CoV-2 infection and mRNA COVID-19 Vaccination—PCORnet, United States, January 2021-January 2022. *MMWR Morb Mortal Wkly Rep*. 2022;71(14):517-523. doi:10.15585/mmwr.mm7114e1
2. Roth GA, Vaduganathan M, Mensah GA. Impact of the COVID-19 pandemic on cardiovascular health in 2020: JACC state-of-the-art review. *J Am Coll Cardiol*. 2022;80(6):631-640. doi:10.1016/j.jacc.2022.06.008
3. Bhatt AS, Moscone A, McElrath EE, et al. Fewer hospitalizations for acute cardiovascular conditions during the COVID-19 pandemic. *J Am Coll Cardiol*. 2020;76(3):280-288. doi:10.1016/j.jacc.2020.05.038
4. Solomon MD, McNulty EJ, Rana JS, et al. The Covid-19 pandemic and the incidence of acute myocardial infarction. *N Engl J Med*. 2020;383(7):691-693. doi:10.1056/NEJMc2015630
5. Kansagra AP, Goyal MS, Hamilton S, Albers GW. Collateral effect of Covid-19 on stroke evaluation in the United States. *N Engl J Med*. 2020;383(4):400-401. doi:10.1056/NEJMc2014816
6. Wadhera RK, Shen C, Gondi S, Chen S, Kazi DS, Yeh RW. Cardiovascular deaths during the COVID-19 pandemic in the United States. *J Am Coll Cardiol*. 2021;77(2):159-169. doi:10.1016/j.jacc.2020.10.055

SUPPLEMENT 1.

eMethods

eTable 1. Population Characteristics in March 2017, 2020, and 2021

eTable 2. Population Characteristics in March 2017, 2020, and 2021 of Study Members from Connecticut, and Analogous Characteristics of the Overall Connecticut Population, Based on the 2014-2018 American Community Survey at the Census Tract Level

eTable 3. Population Characteristics in March 2017, 2020, and 2021 of Study Members from Massachusetts, and Analogous Characteristics of the Overall Massachusetts Population, Based on the 2014-2018 American Community Survey at the Census Tract Level

eTable 4. Population Characteristics in March 2017, 2020, and 2021 of Study Members from Maine, and Analogous Characteristics of the Overall Maine Population, Based on the 2014-2018 American Community Survey at the Census Tract Level

eTable 5. Population Characteristics in March 2017, 2020, and 2021 of Study Members from New Hampshire, and Analogous Characteristics of the Overall New Hampshire Population, Based on the 2014-2018 American Community Survey at the Census Tract Level

eTable 6. Billing Codes Used to Identify High-Acuity Cardiovascular Events

eReferences

SUPPLEMENT 2.

Data Sharing Statement